Abstract |
Excessive fructose absorption and its subsequent metabolisms are implicated in nonalcoholic fatty liver disease, obesity, and insulin resistance in humans. Ketohexokinase (KHK) is a primary enzyme involved in fructose metabolism via the conversion of fructose to fructose-1-phosphate. KHK inhibition might be a potential approach for the treatment of metabolic disorders. Herein, a series of novel KHK inhibitors were designed, synthesized, and evaluated. Among them, compound 14 exhibited more potent activity than PF-06835919 based on the rat KHK inhibition assay in vivo, and higher drug distribution concentration in the liver. Its good absorption, distribution, metabolism, and excretion and pharmacokinetic properties make it a promising clinical candidate.
|
Authors | Guodong Zhu, Jiao Li, Xiaoyan Lin, Zhen Zhang, Tao Hu, Shuhua Huo, Yunfei Li |
Journal | Journal of medicinal chemistry
(J Med Chem)
Vol. 66
Issue 19
Pg. 13501-13515
(10 12 2023)
ISSN: 1520-4804 [Electronic] United States |
PMID | 37766386
(Publication Type: Journal Article)
|
Chemical References |
- Fructokinases
- Fructose
- ketohexokinase
|
Topics |
- Animals
- Humans
- Rats
- Fructokinases
(antagonists & inhibitors)
- Fructose
- Insulin Resistance
- Liver
(metabolism)
- Metabolic Diseases
(drug therapy)
|